OSR (NASDAQ:OSRH – Get Free Report) released its earnings results on Wednesday. The company reported ($0.10) earnings per share (EPS) for the quarter, Zacks reports.
OSR Stock Performance
OSRH stock traded up $0.03 during trading on Wednesday, hitting $0.59. 552,972 shares of the company traded hands, compared to its average volume of 3,259,926. The company has a 50-day moving average of $0.62 and a 200-day moving average of $0.94. OSR has a 1 year low of $0.45 and a 1 year high of $13.40. The firm has a market capitalization of $12.83 million, a PE ratio of -0.58 and a beta of 1.41.
Wall Street Analyst Weigh In
A number of analysts recently issued reports on the stock. Wall Street Zen upgraded shares of OSR to a “sell” rating in a report on Saturday, October 18th. Weiss Ratings restated a “sell (d)” rating on shares of OSR in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock has a consensus rating of “Sell”.
OSR Company Profile
OSR Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D “platform technologies” versus “assets only” companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials.
Featured Stories
- Five stocks we like better than OSR
- Earnings Per Share Calculator: How to Calculate EPS
- Why Bulls Should Want a Bigger Drop in Palantir Stock
- 3 Stocks to Consider Buying in October
- Papa John’s $2.7 Billion Takeover Bid: A Price on Untapped Value
- Stock Dividend Cuts Happen Are You Ready?
- Is Qualcomm Up 40% or Down 20%? 2 Contrarian Takes
Receive News & Ratings for OSR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OSR and related companies with MarketBeat.com's FREE daily email newsletter.
